Diginex's explosive growth is an illusion due to a one-time deal, and is not indicative of future growth rates. Read why DGNX stock is a sell.

Galectin Therapeutics Inc. is rated a Hold due to absence of finalized agreement with FDA, combined with a tight runway. Read ...

Pesticides and disinfection by-products are widely detected together in treated drinking water at trace levels worldwide.

The bank provided more information Thursday as its deal with Fifth Third has drawn litigation alleging a lack of transparency ...

McEwen's latest narrative update leaves its fair value estimate steady at $22.20 per share, even as subtle shifts in key assumptions reshape how investors frame the stock's risk and growth profile. A ...

NAV is the definitive metric for evaluating public companies with significant bitcoin reserves. Unlike traditional book value ...

"Hearst Magazines and Yahoo may earn commission or revenue on some items through these links." This story is part of a series on navigating the new world of peak protein, from the latest packaged ...

The richest man in the world could more than double his $460.6 billion fortune if SpaceX succeeds in going public next year at a valuation of $1.5 trillion. Elon Musk's stake in his space company ...

Add articles to your saved list and come back to them any time. The richest man in the world could more than double his $US460.6 billion ($689.4 billion) fortune if ...

The richest man in the world could more than double his $460.6 billion fortune if SpaceX succeeds in going public next year at a valuation of $1.5 trillion. Elon Musk’s stake in his space company ...

The richest man in the world could more than double his $US460.6 billion ($689.4 billion) fortune if SpaceX succeeds in going public next year at a valuation of $US1 ...